Year: 2019
Type: review
Abstract: The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to important improvements in patient outcomes. However, it is still necessary to increase individualisation of treatments based on tumour genetic profiles to optimise efficacy, while minimising toxicity. As such, there is currently great focus on the discovery and validation of further biomarkers in mCRC, with many new potential prognostic and predictive markers being identified alongside developments in patient molecular profiling technologies. Here, we review data for validated and emerging biomarkers impacting treatment strategies in mCRC. We completed a structured literature search of the PubMed database to identify relevant publications, limiting for English-language publications published between 1 January 2014 and 11 July 2018. In addition, we performed a manual search of the key general oncology and CRC-focused congresses to identify abstracts reporting emerging mCRC biomarker data, and of ClinicalTrials.gov to identify ongoing clinical trials investigating emerging biomarkers in mCRC and/or molecular-guided clinical trials. There is solid evidence supporting the use of BRAF status as a prognostic biomarker and DYPD, UGT1A1, RAS, and microsatellite instability as predictive biomarkers in mCRC. There are a number of emerging biomarkers that may prove to be clinically relevant in the future to have prognostic (HPP1 methylation), predictive (HER3, microRNAs, anti-angiogenic markers, and CRC intrinsic subtypes), or both prognostic and predictive values (HER2, CpG island methylator phenotype, tumour mutational load, gene fusions, and consensus molecular subtypes). As such, new biomarker-led treatment strategies in addition to anti-epidermal growth factor receptor and anti-angiogenetic treatments are being explored. Biomarkers that are not recommended to be tested in clinical practice or are unlikely to be imminently clinically relevant for mCRC include thymidylate transferase, ERCC1, PIK3CA, and PTEN. We highlight the clinical utility of existing and emerging biomarkers in mCRC and provide recommended treatment strategies according to the biomarker status. An update on ongoing molecular-guided clinical trials is also provided.
Source: Drugs
Institutions: Sorbonne Paris Cité, Hôpital Européen Georges-Pompidou, Université Paris Descartes, Pathologisches Institut, Ludwig-Maximilians-Universität München, University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Antwerp University Hospital, St James's University Hospital, Amgen (Switzerland), Hospital Del Mar, Hospital del Mar Research Institute, Centro de Investigación Biomédica en Red de Cáncer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: metastatic colorectal cancer, biomarkers, targeted therapy, treatment selection, BRAF status, predictive biomarkers, prognostic factors, UGT1A1, Ras, microsatellite instability, HER3, microRNA, consensus molecular subtypes, CpG island methylator phenotype, gene fusion, HER2, molecular profiling
Open Access status: hybrid
Estimated APC paid: $3,760
Funders: Amgen, Cancer Research UK
Award: G825715817
OpenAlex ID: W2964344676
